Biotech companies report on drugs to treat head and neck, lung cancers

06/7/2004 | Reuters · Wall Street Journal, The

Genentech and ImClone reported success in developing a pair of drugs that treat head and neck cancer and lung cancer, respectively. Genentech said combining its Tarceva and Avastin can extend the survival rate of patients with lung cancer and ImClone said Erbitux, FDA-approved for treating colon cancer, can work with radiation to increase the median survival rate of patients with head and neck cancer.

View Full Article in:

Reuters · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY